Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 4Pathologic Complete Response 2Multiple Myeloma 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Mesothelioma, Malignant 1Melanoma 1Colorectal Neoplasms 1

Interventions

sargramostim 2Monatide (IMS 3015) 2Granulocyte-Macrophage Colony-Stimulating Factor 2Azacitidine 2venetoclax 1ruxolitinib 1rucaparib 1olaparib 1cc-486 1Pemetrexed 1Observation 1Nivolumab 1Decitabine 1Cytarabine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Pathologic Complete Response × Monatide (IMS 3015) × Clear all
NCT04229979 2025-10-01

REGAL

Sellas Life Sciences Group

Phase 3 Active not recruiting
127 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01266083 2024-11-19

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Sellas Life Sciences Group

Phase 2 Completed
22 enrolled 8 charts
LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡